VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European ...

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an ...

Katie Medrano, program manager in the Office of Research and Sponsored Programs, noted that three performers (a band, Cade ...

Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.

The abstracts will be available on the AACR 2025 meeting website. The posters will be available online at Erasca.com/science/presentations following the presentations.

today announced a poster regarding the Company’s clinical asset, CT-95, a mesothelin (“MSLN”) x CD3 TCE will be presented at the American Association for Cancer Research (AACR) Annual ...

The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients ... or implied are discussed in greater detail in the ...

Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting. Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional ant ...

today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 ...